Peer-reviewed veterinary case report
Chronic feG-COOH treatment reduces airway inflammation in cats
By Eberhardt, Jason M et al.·Published in Veterinary immunology and immunopathology·2009·Department of Veterinary Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Chronic use of the immunomodulating tripeptide feG-COOH in experimental feline asthma.
- Species:
- cat
Plain-English summary
A group of cats with asthma were given a treatment called feG-COOH for two weeks to see if it would help reduce their breathing problems caused by allergies to Bermuda grass. Unfortunately, the treatment did not significantly improve their airway inflammation or asthma symptoms compared to a placebo. This means that feG-COOH alone is not recommended as a treatment for cats with allergic asthma. Pet owners should consult their veterinarian for alternative therapies.
People also search for: cat asthma treatment · feline asthma symptoms · feG-COOH for cats
Abstract
We have previously documented that a single dose of feG-COOH prior to allergen challenge significantly decreased eosinophilic airway inflammation in cats with experimental asthma, but did not result in complete resolution of airway inflammation. This study was undertaken to determine if a chronic (2 weeks) course of feG-COOH in experimentally asthmatic cats would induce complete remission of airway inflammation and clinical signs of asthma. Experimental asthma was induced using Bermuda grass allergen (BGA) and cats were randomly selected to receive either feG-COOH (1mg/kg, PO) or saline for 2 weeks, followed by a 2-week washout period. Cats then received the alternate treatment. Aerosol challenge with BGA was performed weekly throughout the study and bronchoalveolar lavage fluid (BALF) and blood were collected prior to and after each of the 2-week treatment periods. Regular use of feG-COOH had no significant effect on airway inflammation, BALF and plasma TNF bioactivity or a clinical sign compared to placebo. Regular use of feG-COOH can thus not be recommended as the sole therapy for feline allergic asthma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19577809/